Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01664182
Title Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

renal cell carcinoma

Therapies

Sunitinib + Trebananib

Pazopanib + Trebananib

Sorafenib + Trebananib

Trebananib

Bevacizumab + Trebananib

Age Groups: adult
Covered Countries USA


No variant requirements are available.